Cargando…

Combined Application of Patient-Derived Cells and Biomaterials as 3D In Vitro Tumor Models

SIMPLE SUMMARY: For years, cancer has remained the second leading cause of death in U.S. and Europe even though cancer mortality has decreased, as new advances in medical treatment have made this decrease possible. Chemotherapy has remained the gold standard and “one-size-fits-all” treatment for can...

Descripción completa

Detalles Bibliográficos
Autores principales: Hasbum, Asbiel, Karabulut, Ozan, Reyes, Ruben Edgar, Ricci, Claudio, Franchi, Alessandro, Danti, Serena, Chew, Sue Anne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9139582/
https://www.ncbi.nlm.nih.gov/pubmed/35626107
http://dx.doi.org/10.3390/cancers14102503
_version_ 1784714892788367360
author Hasbum, Asbiel
Karabulut, Ozan
Reyes, Ruben Edgar
Ricci, Claudio
Franchi, Alessandro
Danti, Serena
Chew, Sue Anne
author_facet Hasbum, Asbiel
Karabulut, Ozan
Reyes, Ruben Edgar
Ricci, Claudio
Franchi, Alessandro
Danti, Serena
Chew, Sue Anne
author_sort Hasbum, Asbiel
collection PubMed
description SIMPLE SUMMARY: For years, cancer has remained the second leading cause of death in U.S. and Europe even though cancer mortality has decreased, as new advances in medical treatment have made this decrease possible. Chemotherapy has remained the gold standard and “one-size-fits-all” treatment for cancer, yet this approach has lacked precision and, at times, failed. Recent studies attempt to mimic the spatial microenvironment of cancer tissue to better study chemotherapy agents by combining patient-derived cells and three-dimensional (3D) scaffold, bioprinting, spheroid, and hydrogel culturing. This commentary aims to collect and discuss recent findings concerning the combined application of biomaterials with patient-derived cancer cells to better study and test therapies in vitro, that will further personalize and facilitate the treatment of various cancers, and also address the limitation and challenges in developing these 3D models. ABSTRACT: Although advances have been made in cancer therapy, cancer remains the second leading cause of death in the U.S. and Europe, and thus efforts to continue to study and discover better treatment methods are ongoing. Three-dimensional (3D) tumor models have shown advantages over bi-dimensional (2D) cultures in evaluating the efficacy of chemotherapy. This commentary aims to highlight the potential of combined application of biomaterials with patient-derived cancer cells as a 3D in vitro model for the study and treatment of cancer patients. Five studies were discussed which demonstrate and provided early evidence to create 3D models with accurate microenvironments that are comparable to in vivo tumors. To date, the use of patient-derived cells for a more personalized approach to healthcare in combination with biomaterials to create a 3D tumor is still relatively new and uncommon for application in clinics. Although highly promising, it is important to acknowledge the current limitations and challenges of developing these innovative in vitro models, including the need for biologists and laboratory technicians to become familiar with biomaterial scaffolds, and the effort for bioengineers to create easy-to-handle scaffolds for routine assessment.
format Online
Article
Text
id pubmed-9139582
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-91395822022-05-28 Combined Application of Patient-Derived Cells and Biomaterials as 3D In Vitro Tumor Models Hasbum, Asbiel Karabulut, Ozan Reyes, Ruben Edgar Ricci, Claudio Franchi, Alessandro Danti, Serena Chew, Sue Anne Cancers (Basel) Commentary SIMPLE SUMMARY: For years, cancer has remained the second leading cause of death in U.S. and Europe even though cancer mortality has decreased, as new advances in medical treatment have made this decrease possible. Chemotherapy has remained the gold standard and “one-size-fits-all” treatment for cancer, yet this approach has lacked precision and, at times, failed. Recent studies attempt to mimic the spatial microenvironment of cancer tissue to better study chemotherapy agents by combining patient-derived cells and three-dimensional (3D) scaffold, bioprinting, spheroid, and hydrogel culturing. This commentary aims to collect and discuss recent findings concerning the combined application of biomaterials with patient-derived cancer cells to better study and test therapies in vitro, that will further personalize and facilitate the treatment of various cancers, and also address the limitation and challenges in developing these 3D models. ABSTRACT: Although advances have been made in cancer therapy, cancer remains the second leading cause of death in the U.S. and Europe, and thus efforts to continue to study and discover better treatment methods are ongoing. Three-dimensional (3D) tumor models have shown advantages over bi-dimensional (2D) cultures in evaluating the efficacy of chemotherapy. This commentary aims to highlight the potential of combined application of biomaterials with patient-derived cancer cells as a 3D in vitro model for the study and treatment of cancer patients. Five studies were discussed which demonstrate and provided early evidence to create 3D models with accurate microenvironments that are comparable to in vivo tumors. To date, the use of patient-derived cells for a more personalized approach to healthcare in combination with biomaterials to create a 3D tumor is still relatively new and uncommon for application in clinics. Although highly promising, it is important to acknowledge the current limitations and challenges of developing these innovative in vitro models, including the need for biologists and laboratory technicians to become familiar with biomaterial scaffolds, and the effort for bioengineers to create easy-to-handle scaffolds for routine assessment. MDPI 2022-05-19 /pmc/articles/PMC9139582/ /pubmed/35626107 http://dx.doi.org/10.3390/cancers14102503 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Commentary
Hasbum, Asbiel
Karabulut, Ozan
Reyes, Ruben Edgar
Ricci, Claudio
Franchi, Alessandro
Danti, Serena
Chew, Sue Anne
Combined Application of Patient-Derived Cells and Biomaterials as 3D In Vitro Tumor Models
title Combined Application of Patient-Derived Cells and Biomaterials as 3D In Vitro Tumor Models
title_full Combined Application of Patient-Derived Cells and Biomaterials as 3D In Vitro Tumor Models
title_fullStr Combined Application of Patient-Derived Cells and Biomaterials as 3D In Vitro Tumor Models
title_full_unstemmed Combined Application of Patient-Derived Cells and Biomaterials as 3D In Vitro Tumor Models
title_short Combined Application of Patient-Derived Cells and Biomaterials as 3D In Vitro Tumor Models
title_sort combined application of patient-derived cells and biomaterials as 3d in vitro tumor models
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9139582/
https://www.ncbi.nlm.nih.gov/pubmed/35626107
http://dx.doi.org/10.3390/cancers14102503
work_keys_str_mv AT hasbumasbiel combinedapplicationofpatientderivedcellsandbiomaterialsas3dinvitrotumormodels
AT karabulutozan combinedapplicationofpatientderivedcellsandbiomaterialsas3dinvitrotumormodels
AT reyesrubenedgar combinedapplicationofpatientderivedcellsandbiomaterialsas3dinvitrotumormodels
AT ricciclaudio combinedapplicationofpatientderivedcellsandbiomaterialsas3dinvitrotumormodels
AT franchialessandro combinedapplicationofpatientderivedcellsandbiomaterialsas3dinvitrotumormodels
AT dantiserena combinedapplicationofpatientderivedcellsandbiomaterialsas3dinvitrotumormodels
AT chewsueanne combinedapplicationofpatientderivedcellsandbiomaterialsas3dinvitrotumormodels